Answers are grounded in this paper and cite their sources.
The number of patients requiring palliative care is increasing every day due to population ageing and the increase in degenerative and chronic diseases [1]. These patients can be particularly vulnerable to infection due to immune dysfunction, especially after chemotherapy regimens in those with cancer, or as a result of multiple comorbid conditions and complex diseases [2-5]. One third of terminally ill patients develop infections during their final phase of care [4]. The percentage of patients using antibiotics in hospice care ranges from 36% to 84% [5-6]. Antibiotic therapy for the management of neutropenia and non-neutropenic haematologic diseases has been widely described and is regularly updated. However, there is little information regarding the management of antibiotic therapy in palliative care patients [4-7].
No takes yet. Share an insight, caveat, or question.
Gallardo et al. (2017) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: